Well.... fairly large market cap, no cash. Cash runway will last until important data is in, but, still not the norm.
There are three arms, plasminogen, 4050, and plasma protein tech.
Early in career, I worked for a plasma fractionation joint (Bayer). Even then, we had an interest in plasminogen. But it copurified (from Cohn fractionation-derived materials) with some pre-thrombotic garbage. So their "avoiding Cohn" story makes sense. But three decades later, and they're the only competitors close to a launch (if!)? Gives pause, makes one wonder about future hurdles (marketing/regulatory).
4050 is difficult to track. All of their small molecules changed designation with a corporate name change. They have two proprietary molecule classes, and that's about all I know. All of the company's descriptions do not assign a target. In any event, 4050 is getting no respect (deserved or not, that's the question we need to answer)..... the markets addressed are huge.
Plasma protein tech looks top shelf, first glance. Hope so.
Lots of work to do before I'll have an opinion.
Welcome to S.I.! |
